triazoles has been researched along with gsk1210151a in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 16 (80.00) | 24.3611 |
2020's | 4 (20.00) | 2.80 |
Authors | Studies |
---|---|
Aull, K; Boehm, D; Bradner, JE; Calvanese, V; Dar, RD; Li, PC; Martins, L; Ott, M; Planelles, V; Schroeder, S; Siliciano, RF; Verdin, E; Weinberger, L; Xing, S; Zhou, MM | 1 |
Chaudhary, PM; Gopalakrishnan, R; Matta, H; Punj, V; Tolani, B | 1 |
Bentrem, DJ; Chow, CR; Ebine, K; Knab, LM; Kumar, K; Kwok, B; Licht, JD; Munshi, HG; Popovic, R; Raza, SS | 1 |
Choi, TY; Ko, S; Monga, SPS; Russell, JO; Shin, D; So, J | 1 |
Cai, MC; Di, W; Gao, WQ; Gu, Z; Ji, ZL; Jing, Y; Ma, P; Peng, H; Yan, Y; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G | 1 |
Aiba, K; Arakawa, Y; Kitagawa, M; Suzuki, K; Yamada, H; Yamamoto, K | 1 |
Atmadibrata, B; Liu, PY; Liu, T; Mondal, S; Tee, AE | 1 |
Angus, SP; Beltran, AS; Bevill, SM; Carey, LA; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Gallagher, K; Golitz, BT; Goulet, DR; Graves, LM; He, X; Johnson, GL; Olivares-Quintero, JF; Parker, JS; Perou, CM; Rashid, NU; Santos, C; Sciaky, N; Singh, D; Stuhlmiller, TJ; Velarde, SH; Whittle, MC; Zawistowski, JS | 1 |
Bentrem, DJ; DeCant, BT; Ebine, K; Grippo, PJ; Hwang, RF; Kumar, K; Munshi, HG | 1 |
Adcock, IM; Barnes, PJ; Durham, AL; Fear, D; Lee, JS; Russell, KE; Shim, JM; Wiegman, CH | 1 |
Ando, A; Baba, Y; Ebara, S; Hara, T; Kitazawa, S; Satomi, Y; Soga, T | 1 |
Connelly, CJ; Greider, CW; Lee, SS; Pike, AM; Strong, MA; Wang, S | 1 |
Allegri, L; Baldan, F; Conzatti, K; Damante, G; Filetti, S; Mio, C; Rosignolo, F; Russo, D; Sponziello, M | 1 |
Cheng, Z; Gao, Z; Li, P; Ni, P; Sun, G; Wang, X; Yuan, T; Zhou, X | 1 |
Aiello, V; Berthault, C; Grapin-Botton, A; Hansson, M; Honore, C; Huijbregts, L; Petersen, MBK; Rachdi, L; Scharfmann, R | 1 |
Bereta, G; Bysiek, A; Chomyszyn-Gajewska, M; Gawron, K; Grabiec, AM; Kantorowicz, M; Lagosz, KB; Macina, JM; Maksylewicz, A; Potempa, J; Sochalska, M | 1 |
Potluri, A; Radhakrishnan, SK; Vangala, JR | 1 |
Bauersachs, J; Daniel, JM; Dutzmann, J; Gegel, S; Haertlé, M; Kalies, K; Kloss, F; Knöpp, K; Musmann, RJ; Pilowski, C; Sedding, DG; Sieweke, JT; Sirisko, M | 1 |
Chen, Y; Jin, H; Li, J; Lu, Z; Mi, Y; Qiao, J; Wang, L; Wang, Q; Zou, Z | 1 |
Chen, J; Cheng, Z; Luo, J; Meng, Y; Sun, T; Wang, X; Xia, B; Zhang, Z; Zhou, X | 1 |
1 trial(s) available for triazoles and gsk1210151a
Article | Year |
---|---|
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Discoidin Domain Receptor 1; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Epigenesis, Genetic; Female; Heterocyclic Compounds, 4 or More Rings; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice, Inbred BALB C; Mice, SCID; Molecular Targeted Therapy; Nuclear Proteins; Positive Transcriptional Elongation Factor B; Pyridones; Pyrimidinones; RNA Interference; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
19 other study(ies) available for triazoles and gsk1210151a
Article | Year |
---|---|
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
Topics: Azepines; Benzodiazepines; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Cells, Cultured; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Jurkat Cells; Nuclear Proteins; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Transcription, Genetic; Triazoles; Virus Latency | 2013 |
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cellular Senescence; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Herpesvirus 8, Human; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Lymphoma, Primary Effusion; Nuclear Proteins; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Transcription Factors; Transcription, Genetic; Triazoles; Tumor Burden; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
Topics: Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Kruppel-Like Transcription Factors; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Signal Transduction; Transcriptional Activation; Triazoles; Xenograft Model Antitumor Assays; Zinc Finger Protein Gli2 | 2015 |
Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration.
Topics: Animals; Azepines; Biliary Tract; Cell Line; Cell Proliferation; Cell Transdifferentiation; Epithelial Cells; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Liver; Liver Regeneration; Mice; Organ Size; Transcription Factors; Transcriptional Activation; Triazoles; Zebrafish | 2016 |
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma; Cell Line, Tumor; Down-Regulation; Female; Forkhead Box Protein M1; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Pteridines; Transcription Factors; Triazoles | 2016 |
Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Targeted Therapy; Multiple Myeloma; N-Myc Proto-Oncogene Protein; Protein Domains; Proto-Oncogene Proteins c-myc; Triazoles | 2016 |
NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Topics: Azepines; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Histones; Humans; Methylation; Neoplasm Proteins; Neuroblastoma; Nuclear Matrix-Associated Proteins; Octamer Transcription Factors; Prognosis; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Long Noncoding; RNA, Messenger; RNA, Small Interfering; Triazoles | 2016 |
BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Topics: Animals; Azepines; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Collagen Type I; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Nuclear Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins p21(ras); RNA-Binding Proteins; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2017 |
BET proteins are a key component of immunoglobulin gene expression.
Topics: Animals; Azepines; B-Lymphocytes; Cell Cycle Proteins; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Gene Expression Regulation; Heterocyclic Compounds, 4 or More Rings; Humans; Immunoglobulin G; Mice; Nuclear Proteins; Organic Cation Transport Proteins; Organic Cation Transporter 2; Promoter Regions, Genetic; Transcription Factors; Triazoles | 2017 |
Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors.
Topics: Antineoplastic Agents; Azepines; Benzodiazepines; Citric Acid Cycle; CRISPR-Cas Systems; Dehydroepiandrosterone; Fumarates; Gene Knockout Techniques; Glucosephosphate Dehydrogenase; Glycolysis; HCT116 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Metabolomics; Mitochondria; Mutation; Neoplasms; Oxygen Consumption; Phenformin; Phosphoglycerate Dehydrogenase; Proto-Oncogene Proteins c-myc; RNA Interference; RNA, Small Interfering; Succinate Dehydrogenase; Succinic Acid; Triazoles | 2017 |
BRD4 inhibitors block telomere elongation.
Topics: Acetanilides; Animals; Azepines; Blotting, Southern; Cell Cycle Proteins; Cell Line; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; In Situ Hybridization, Fluorescence; Mice; Morpholines; Nuclear Proteins; Pyrones; RNA Interference; Telomerase; Telomere; Telomere Homeostasis; Telomere Shortening; Transcription Factors; Triazoles | 2017 |
BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Benzodiazepines; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; MicroRNAs; Phosphorylation; STAT3 Transcription Factor; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Triazoles | 2018 |
Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Topics: A549 Cells; Animals; Azepines; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Eukaryotic Initiation Factor-4E; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Nuclear Proteins; Random Allocation; Transcription Factors; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Bromodomain and Extra Terminal Protein Inhibitors Promote Pancreatic Endocrine Cell Fate.
Topics: Animals; Azepines; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Proliferation; Heterocyclic Compounds, 4 or More Rings; Humans; Induced Pluripotent Stem Cells; Insulin-Secreting Cells; Islets of Langerhans; Mice; Nerve Tissue Proteins; Proteins; Signal Transduction; Triazoles | 2019 |
BET Bromodomain Inhibitors Suppress Inflammatory Activation of Gingival Fibroblasts and Epithelial Cells From Periodontitis Patients.
Topics: Animals; Azepines; Cytokines; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Gingiva; Heterocyclic Compounds, 4 or More Rings; Humans; Inflammation; Mice; Periodontitis; Porphyromonas gingivalis; Triazoles | 2019 |
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzodiazepines; Cell Death; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 4 or More Rings; Humans; NF-E2-Related Factor 1; Oligopeptides; Proteasome Inhibitors; Triazoles; Unfolded Protein Response | 2020 |
BET bromodomain-containing epigenetic reader proteins regulate vascular smooth muscle cell proliferation and neointima formation.
Topics: Animals; Azepines; Carotid Artery Injuries; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Coronary Vessels; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Forkhead Box Protein O1; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Nuclear Proteins; Proteins; Signal Transduction; Transcription Factors; Triazoles; Vascular System Injuries | 2021 |
ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
Topics: A549 Cells; Activating Transcription Factor 2; Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Feedback, Physiological; Female; Ferroptosis; HeLa Cells; Heterocyclic Compounds, 4 or More Rings; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms; NF-E2-Related Factor 2; Proteins; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2021 |
BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Prognosis; Signal Transduction; Transcription Factors; Triazoles | 2021 |